Exemptia 40mg Injection

• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Crohn's Disease
• Ulcerative Colitis
• Plaque Psoriasis
• Juvenile Idiopathic Arthritis
• Uveitis

• Hidradenitis Suppurativa​
  

​Exemptia 40mg Injection can cause multiple side effects, most of which are mild to moderate and often temporary. Patients are advised to inform their healthcare provider immediately if symptoms stay for a prolonged period of time.

Common side effects include:

• Injection site reactions

• Rash

• Headache

• Sinusitis

• Upper respiratory infections

• Fever

Serious side effects include:

• Heart problems

• Abnormal heartbeat

• Severe skin reactions

• Abnormal blood count values

• Liver injury

• Bone problems

• Infections (tuberculosis)

• ​The recommended dose of Exemptia 40mg Injection may vary according to the type of disease, as well as age, weight, and other health factors of the patients.
• It should be given under the skin (subcutaneously) by a doctor or experienced nurse.
• Don't self-administer the injection, and don't double the dose to compensate for the missed dose.​

If you miss a dose, contact your health professional as soon as possible. Try not to miss or skip your dosage of Exemptia injection.

 At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• Navarro‐Sarabia, F., Ariza‐Ariza, R., Hernandez‐Cruz, B., & Villanueva, I. (2005). Adalimumab for treating rheumatoid arthritis. The Cochrane Database of Systematic Reviews, 2005(3), CD005113.
• Lapadula, G., Marchesoni, A., Armuzzi, A., Blandizzi, C., Caporali, R., Chimenti, S., ... & Salvarani, C. (2014). Adalimumab in the treatment of immune-mediated diseases. International Journal of Immunopathology and Pharmacology, 27(1_suppl), 33-48.
• Bartelds, G. M., Wijbrandts, C. A., Nurmohamed, M. T., Stapel, S., Lems, W. F., Aarden, L., ... & Wolbink, G. J. (2007). Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Annals of the rheumatic diseases, 66(7), 921-926.
• Kapoor, S., Kaushik, V. K., Jain, R., Rao, V. K. R., Gharia, M., et al. (2019). Real‑life tolerability and effectiveness of adalimumab biosimilar in ankylosing spondylitis: Adalimumab Biosimilar Patient Registry data. ACR Open Rheumatology, 1(8), 480–484 - https://doi.org/10.1002/acr2.11067
• Midha, Y., Kumar, N., Singhal, S., et al. (2023). Efficacy and safety of Exemptia™ (biosimilar adalimumab) in moderate-to-severe steroid-refractory ulcerative colitis: 24-week follow-up in a real-world setting. Biologics: Targets & Therapy (retrospective analysis). Patil, S. (2018). Low‑dose adalimumab biosimilar (ZRC‑3197) in the treatment of hidradenitis suppurativa. Indian Journal of Dermatology, Venereology and Leprology, 84(5), 745–747.